These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 15667875)

  • 41. Characterization of rectal normal tissue complication probability after high-dose external beam radiotherapy for prostate cancer.
    Cheung R; Tucker SL; Ye JS; Dong L; Liu H; Huang E; Mohan R; Kuban D
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1513-9. PubMed ID: 15050331
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Conformal radiotherapy for patients with clinical stage T1-T3 prostate cancer].
    Majewski W; Miszczyk L; Zajusz A
    Przegl Lek; 2004; 61(5):503-8. PubMed ID: 15515815
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy.
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):397-405. PubMed ID: 15890581
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
    Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M
    Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison.
    Leborgne F; Fowler J
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1441-6. PubMed ID: 19395194
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Three-dimensional conformal radiotherapy versus intracavitary brachytherapy for salvage treatment of locally persistent nasopharyngeal carcinoma.
    Zheng XK; Chen LH; Chen YQ; Deng XG
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):165-70. PubMed ID: 15337552
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study.
    Fellin G; Fiorino C; Rancati T; Vavassori V; Baccolini M; Bianchi C; Cagna E; Gabriele P; Mauro F; Menegotti L; Monti AF; Stasi M; Valdagni R
    Radiother Oncol; 2009 Nov; 93(2):197-202. PubMed ID: 19828205
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity.
    Karlsdóttir A; Muren LP; Wentzel-Larsen T; Dahl O
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1478-86. PubMed ID: 18060703
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial.
    Arcangeli S; Strigari L; Soete G; De Meerleer G; Gomellini S; Fonteyne V; Storme G; Arcangeli G
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):39-45. PubMed ID: 18538488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
    Ryan CJ; Zelefsky MJ; Heller G; Regan K; Leibel SA; Scher HI; Kelly WK
    Urology; 2004 Jul; 64(1):90-4. PubMed ID: 15245942
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
    Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy.
    Valdagni R; Italia C; Montanaro P; Lanceni A; Lattuada P; Magnani T; Fiorino C; Nahum A
    Radiother Oncol; 2005 Apr; 75(1):74-82. PubMed ID: 15878104
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dose escalation for prostate cancer using the three-dimensional conformal dynamic arc technique: analysis of 542 consecutive patients.
    Jereczek-Fossa BA; Vavassori A; Fodor C; Santoro L; Zerini D; Cattani F; Garibaldi C; Cambria R; Fodor A; Boboc GI; Vitolo V; Ivaldi GB; Musi G; de Cobelli O; Orecchia R
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):784-94. PubMed ID: 18191332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Late rectal and urinary toxicity from conformal, dose-escalated radiation therapy for prostate cancer: a prospective study of 402 patients.
    Lin C; Turner S; Mai T; Kneebone A; Gebski V
    Australas Radiol; 2007 Dec; 51(6):578-83. PubMed ID: 17958696
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
    Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical correlations between treatment with anticoagulants/antiaggregants and late rectal toxicity after radiotherapy for prostate cancer.
    Takeda K; Ogawa Y; Ariga H; Koto M; Sakayauchi T; Fujimoto K; Narazaki K; Mitsuya M; Takai Y; Yamada S
    Anticancer Res; 2009 May; 29(5):1831-4. PubMed ID: 19443412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.